Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial

Affiliations

¹ Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy.
² Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Universita' Cattolica del Sacro Cuore, Rome 00168, Italy.
³ Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Universita' Cattolica del Sacro Cuore, Rome 00168, Italy. Electronic address: giovanni.scambia@policlinicogemelli.it.

Comment

Valentina Ghirardi et al. Lancet Oncol. 2023 Oct.

. 2023 Oct;24(10):1057-1059.

doi: 10.1016/S1470-2045(23)00447-3.

¹ Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy.
² Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Universita' Cattolica del Sacro Cuore, Rome 00168, Italy.
³ Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Universita' Cattolica del Sacro Cuore, Rome 00168, Italy. Electronic address: giovanni.scambia@policlinicogemelli.it.

No abstract available

Conflict of interest statement

We declare no competing interests.

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Aronson SL, et al. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. Lancet Oncol. 2023. PMID: 37708912 Clinical Trial.